oral CFTR ABC transporter potentiator
Ph. II for cystic fibrosis (5-80 mg QD), discont.
similarity screen of 589 cmpds + scaffold hop
J. Med. Chem., Jan. 5, 2021
Galapagos NV, Mechelen, BE
The Galapagos CFTR potentiator, GLPG2451, is an oral, once-daily clinical candidate for cystic fibrosis (5-80 mg QD). It was advanced into a high-profile Ph. II triple-combo study with the…